(Q34660675)

3 August 2017

Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis (English)

1 reference

3 August 2017

0 references

1 reference

1 reference

ChEBI release 2020-05-28

1 reference

7

Joseph H Friedman

1 reference

3 August 2017

Herbert Y Meltzer

1

1 reference

3 August 2017

Roger Mills

2

1 reference

3 August 2017

Stephen Revell

3

1 reference

3 August 2017

Hilde Williams

4

1 reference

3 August 2017

Ann Johnson

5

1 reference

3 August 2017

Daun Bahr

6

1 reference

3 August 2017

language of work or name

English

0 references

publication date

11 November 2009

1 reference

3 August 2017

Neuropsychopharmacology

1 reference

3 August 2017

35

1 reference

3 August 2017

881-892

1 reference

3 August 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1038/npp.2009.176

3 August 2017

0 references

cites work

A randomized controlled trial of quetiapine for psychosis in Parkinson's disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055369

Hallucinations in Parkinson disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055369

The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055369

A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055369

Scales to assess psychosis in Parkinson's disease: Critique and recommendations

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055369

The management of psychosis in movement disorder patients

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055369

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055369

Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055369

Role of 5HT 2A and 5HT 2C polymorphisms in behavioural and psychological symptoms of Alzheimer's disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055369

Treating dopamimetic psychosis in Parkinson's disease: structured review and meta-analysis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055369

Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055369

Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055369

Risk of death in elderly users of conventional vs. atypical antipsychotic medications

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055369

Psychiatric complications in Parkinson disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055369

Psychotic symptoms in Parkinson's disease. From description to etiology

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055369

Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055369

Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055369

Psychosis in Parkinson's disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055369

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055369

Serotonin receptors: their key role in drugs to treat schizophrenia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055369

Rationale for current therapies in Parkinson’s disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055369

Treatment of psychosis in Parkinson's disease: safety considerations

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055369

The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055369

Localization of 5-HT(2A) receptors on dopamine cells in subnuclei of the midbrain A10 cell group

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055369

M100,907, a selective 5-HT(2A) antagonist, attenuates dopamine release in the rat medial prefrontal cortex

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055369

An overview of side effects caused by typical antipsychotics.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055369

Activation of 5-HT2A/2C receptors within the nucleus accumbens increases local dopaminergic transmission.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055369

Worsening of motor features of parkinsonism with olanzapine

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055369

Statistical principles for clinical trials (ICH E9): an introductory note on an international guideline.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055369

5-HT2 receptor antagonism reduces hyperactivity induced by amphetamine, cocaine, and MK-801 but not D1 agonist C-APB

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055369

Parkinson Psychosis Rating Scale: a practical instrument for grading psychosis in Parkinson's disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055369

Early dopaminergic drug-induced hallucinations in parkinsonian patients

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055369

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055369

Serotonin-dopamine interaction in the rat ventral tegmental area: an electrophysiological study in vivo

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055369

5-Hydroxytryptamine (5-HT)4 receptors in post mortem human brain tissue: distribution, pharmacology and effects of neurodegenerative diseases

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055369

Aminergic systems in Alzheimer's disease and Parkinson's disease.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055369

Serotonin-1 receptor binding sites in the human basal ganglia are decreased in Huntington's chorea but not in Parkinson's disease: a quantitative in vitro autoradiography study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055369

Central D1- and D2-receptor occupancy during antipsychotic drug treatment

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055369

A New Method for Measuring Daytime Sleepiness: The Epworth Sleepiness Scale

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055369

The Management of the Levodopa Psychoses

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055369

5-HT2 receptors exert a state-dependent regulation of dopaminergic function: studies with MDL 100,907 and the amphetamine analogue, 3,4-methylenedioxymethamphetamine

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055369

The dopamine hypothesis of schizophrenia: a review

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055369

Association of the serotonin transporter and receptor gene polymorphisms in neuropsychiatric symptoms in Alzheimer disease

7 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.176

5-HT1B receptor binding in degenerative movement disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.176

Post-synaptic 5-HT1A and 5-HT2A receptors are increased in Parkinson's disease neocortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.176

Longitudinal outcome of Parkinson's disease patients with psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.176

Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.176

Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.176

Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.176

Prospective longitudinal assessment of hallucinations in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.176

5-HT2A and 5-HT2C receptor polymorphisms and psychopathology in late onset Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.176

Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.176

5-HT2A T102C receptor polymorphism and neuropsychiatric symptoms in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.176

Long-term evaluation of the effect of quetiapine on hallucinations, delusions and motor function in advanced Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.176

Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.176

Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson's disease. A high potency effect of clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.176

Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.176

High 5-HT2 receptor occupancy in clozapine treated patients demonstrated by PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.176

Actions of 5-hydroxytryptamine on ventral tegmental area neurons of the rat in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.176

Insular cortex abnormalities in schizophrenia: Relationship to symptoms and typical neuroleptic exposure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.176

Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.176

Morphometry of the superior temporal plane in schizophrenia: relationship to clinical correlates.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055369

Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055369

D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients

26 October 2018

1 reference

12 December 2020

Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis

1 reference

12 December 2020

1 reference

12 December 2020

1 reference

12 December 2020

Clozapine in drug-induced psychosis in Parkinson's disease. The French Clozapine Parkinson Study Group

1 reference

12 December 2020

Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values

1 reference

12 December 2020

Identifiers

DOI

10.1038/NPP.2009.176

1 reference

Dimensions Publication ID

3 August 2017

0 references

1 reference

3 August 2017

1 reference